Skip to main content
All lobbying filings

Orchard Therapeutics North America

Orchard Therapeutics North America filed a Q1 report for Orchard Therapeutics North America on April 17, 2026.

Lobbying for Orchard Therapeutics North America · Health

As filed: ORCHARD THERAPEUTICS NORTH AMERICA for ORCHARD THERAPEUTICS NORTH AMERICA.

All filings by Orchard Therapeutics North America · Everything Orchard Therapeutics North America has reported

 Amended
The filer submitted a later report covering this same period, so the amounts here have been replaced. Site totals count only the latest version. See the current filing, posted Apr 29, 2026.
 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 17, 2026
Expenses
$350,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
Massachusetts

Official filing document

 Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Health Issues

Accelerating Kids' Access to Care Act and Pediatric Priority Review Voucher (Give Kids a Chance Act) FDA Policies: Rare Disease Gene Therapy Approvals Newborn Screening, including HRSA Appropriations & Fundings; RUSP Conditions

Medicare/Medicaid

H.R. 7871: Medicaid Value-Based Payments for Patients (MVP) Act AKATCA and states' awareness of VBA's

 Bills named in this filing 1

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem